In our previous study, highly selective HDAC6 inhibitor 23BB has been designed, synthesized and evaluated for anti-tumor activity and safety in both solid and hematologic tumor models (Figure 1) (Yang et al., 2016). The gene discussed is HDAC6; the disease is neoplasm.